<code id='FBFB352772'></code><style id='FBFB352772'></style>
    • <acronym id='FBFB352772'></acronym>
      <center id='FBFB352772'><center id='FBFB352772'><tfoot id='FBFB352772'></tfoot></center><abbr id='FBFB352772'><dir id='FBFB352772'><tfoot id='FBFB352772'></tfoot><noframes id='FBFB352772'>

    • <optgroup id='FBFB352772'><strike id='FBFB352772'><sup id='FBFB352772'></sup></strike><code id='FBFB352772'></code></optgroup>
        1. <b id='FBFB352772'><label id='FBFB352772'><select id='FBFB352772'><dt id='FBFB352772'><span id='FBFB352772'></span></dt></select></label></b><u id='FBFB352772'></u>
          <i id='FBFB352772'><strike id='FBFB352772'><tt id='FBFB352772'><pre id='FBFB352772'></pre></tt></strike></i>

          hotspot

          hotspot

          author:explore    Page View:9531
          Nasdaq
          Mario Tama/Getty Images

          Neumora, a neuroscience startup founded by VC Arch Venture Partners, hopes to become one of the few biotechs to go public this year.

          The company filed paperwork for an IPO with the Securities and Exchange Commission on Friday. It did not state how many shares it plans to sell or at what price.

          advertisement

          The biotech had begun planning for an IPO last year, STAT reported in June 2022. It raised $112 million in what would turn out to be a crossover round last October.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In

          explore

          Peter Hotez and the public health issue of online harassment
          Peter Hotez and the public health issue of online harassment

          AdobeFather’sDayweekendwasanythingbutcalmonTwitter,whicheruptedasvaccineexpertPeterHotezwaschallenge

          read more
          Sepsis can kill a child within hours. Here's how hospitals are fighting back
          Sepsis can kill a child within hours. Here's how hospitals are fighting back

          ErosDervishiforSTATFORTWORTH,Texas—Itmightstartoutlookinglikenotmuchmorethananordinarychildhoodfever

          read more
          DIEP, the 'gold standard' of breast reconstruction, is under threat
          DIEP, the 'gold standard' of breast reconstruction, is under threat

          AdobeIn1983,Iflewhomefromcollegetobewithmymotherasshewokeupfromamastectomy.Sheoptedoutofbreastrecons

          read more

          Readout Newsletter: PTC, Dyne, Rapport, Cytokinetics news

          MattRourke/APWanttostayontopofthescienceandpoliticsdrivingbiotechtoday? Signup togetourbiotechnewsle